Skip to main content
logo
Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
5.29
+0.25 (4.96%)
Aug 12, 2025, 4:00 PM - Market closed

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
---0.050.45-
Revenue Growth (YoY)
----89.98%--
Cost of Revenue
---0.010.09-
Gross Profit
---0.030.36-
Selling, General & Admin
10.9912.915.9815.96.163.59
Research & Development
8.998.8813.017.263.83.18
Operating Expenses
19.9821.7828.9923.169.966.77
Operating Income
-19.98-21.78-28.99-23.13-9.61-6.77
Interest Expense
-0.53-0.93-1.07-0.16-0.61-0.16
Other Non Operating Income (Expenses)
0.480.511.33-2.130.24-1.05
EBT Excluding Unusual Items
-20.03-22.2-28.73-25.42-9.98-7.99
Other Unusual Items
---0.47--0.060.06
Pretax Income
-20.03-22.2-29.2-25.42-10.92-7.93
Income Tax Expense
0.010.010.020.010.010
Earnings From Continuing Operations
-20.04-22.21-29.22-25.43-10.93-7.94
Minority Interest in Earnings
0.190.07----
Net Income
-19.85-22.14-29.22-25.43-10.93-7.94
Preferred Dividends & Other Adjustments
-1.67----
Net Income to Common
-19.85-23.81-29.22-25.43-10.93-7.94
Shares Outstanding (Basic)
210000
Shares Outstanding (Diluted)
210000
Shares Change (YoY)
509.92%374.79%98.24%-56.93%15.26%-
EPS (Basic)
-11.24-35.70-207.95-358.77-66.44-55.59
EPS (Diluted)
-11.25-35.70-207.95-358.77-66.44-55.59
Free Cash Flow
--19.71-27.57-13.64-7.98-5.18
Free Cash Flow Per Share
--29.55-196.22-192.49-48.49-36.26
Gross Margin
---68.89%79.06%-
Operating Margin
----51395.56%-2139.42%-
Profit Margin
----56504.44%-2434.97%-
Free Cash Flow Margin
----30315.56%-1777.28%-
EBITDA
-19.6-21.37-28.6-22.87-9.45-6.67
D&A For EBITDA
0.380.40.390.260.160.11
EBIT
-19.98-21.78-28.99-23.13-9.61-6.77
Revenue as Reported
---0.05--
Updated May 14, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q